ClinTec Sees Rise in Revenues and Growth in the Middle East
ClinTec, a full service multinational contract research organisation (CRO), has today announced that it has achieved organic growth with a 45 per cent increase in global sales revenues over the last twelve months; expanded its client base and signing new contracts with 11 of the world’s top 25 pharmaceutical firms.
With a presence in some 40 countries around the world, ClinTec International manages clinical trials in all major therapeutic areas, including oncology, neurology, cardiovascular, respiratory as well as gastroenterology.
Dr. Rabinder Buttar, the company’s founder, President and CEO commented: “The launch of our Cairo office in October was one of the high points of the year. Apart from providing our global pharmaceutical associates with access to new patient populations, ClinTec Cairo cements our reputation as the major CRO in the Middle East and North Africa (MENA) region."
ClinTec has played a key role in 2009 in facilitating complex restructuring programmes for Global Pharma, who are searching for innovative ways to optimise their R&D efforts. The shift of research delivery from West to East is an area in which ClinTec is able to offer a credible solution for using a blend between flexible resource solutions and off-shore project delivery.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
